OSA Clinical Trials

649 recruitingLast updated: June 18, 2026

There are 649 actively recruiting osa clinical trials across 64 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


OSA Trials at a Glance

649 actively recruiting trials for osa are listed on ClinicalTrialsFinder across 6 cities in 64 countries. The largest study group is Phase 2 with 173 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running osa studies include Sun Yat-sen University, M.D. Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center.

Treatments under study

About OSA Clinical Trials

Looking for clinical trials for OSA? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new OSA trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about OSA clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 649 trials

Recruiting
Phase 3

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Metastatic Dedifferentiated LiposarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more
National Cancer Institute (NCI)365 enrolled256 locationsNCT06422806
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Metastatic Soft Tissue SarcomaMetastatic LeiomyosarcomaAdvanced Soft Tissue Sarcoma+5 more
National Cancer Institute (NCI)74 enrolled1 locationNCT06498648
Recruiting
Phase 2Phase 3

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Metastatic OsteosarcomaHigh Grade OsteosarcomaLocalized Osteosarcoma+1 more
National Cancer Institute (NCI)1,122 enrolled197 locationsNCT05691478
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Pancreatic CancerHereditary Breast and Ovarian CancerHodgkin Lymphoma+43 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting
Phase 2

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Locally Advanced Rectal AdenocarcinomaMicrosatellite Stable Rectal Carcinoma
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT06843434
Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia

Skin CancerMucosal Neoplasm of Oral CavitySoft Tissue Neoplasm
Alpha Tau Medical LTD.56 enrolled1 locationNCT04534127
Recruiting
Not Applicable

Early Feeding Versus Delayed Feeding After Colorectal Endoscopic Submucosal Dissection

Colorectal NeoplasmsEndoscopic Submucosal Dissection
Pusan National University Hospital204 enrolled5 locationsNCT06805123
Recruiting

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

Genetic diseasesFeverROSAH+4 more
National Human Genome Research Institute (NHGRI)5,000 enrolled5 locationsNCT00001373
Recruiting
Phase 1Phase 2

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Hematopoietic and Lymphatic System NeoplasmMetastatic Malignant Solid NeoplasmStage IV Colorectal Cancer AJCC v8+4 more
National Cancer Institute (NCI)42 enrolled23 locationsNCT05691491
Recruiting

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

ANCA-associated VasculitisGiant Cell ArteritisTakayasu's Arteritis+2 more
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)4,000 enrolled1 locationNCT02257866
Recruiting
Phase 1Phase 2

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Refractory NeuroblastomaRefractory RhabdomyosarcomaRefractory Solid Tumors+3 more
Theodore Laetsch59 enrolled7 locationsNCT06721689
Recruiting
Phase 1

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Castration-Resistant Prostate Cancer (CRPC)ER+, HER 2- Breast Cancer+1 more
IDEAYA Biosciences160 enrolled11 locationsNCT07540572
Recruiting
Phase 1

Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma

OsteosarcomaSoft Tissue Sarcoma (STS)
Sun Yat-sen University16 enrolled1 locationNCT07648069
Recruiting
Early Phase 1

N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

Synovial SarcomaMyxoid LiposarcomaRound Cell Liposarcoma
Seth Pollack8 enrolled1 locationNCT07261657
Recruiting

Cell Collection to Study Eye Diseases

Retinal DegenerationRetinitis PigmentosaRetinal Disease+1 more
National Eye Institute (NEI)930 enrolled1 locationNCT01432847
Recruiting
Phase 2

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Rhabdomyosarcoma
St. Jude Children's Research Hospital135 enrolled3 locationsNCT06023641
Recruiting

Biospecimen Procurement for Head and Neck Disorders

Head and Neck NeoplasmsLaryngeal DiseaseHearing Disorder+2 more
National Cancer Institute (NCI)1,000 enrolled9 locationsNCT03429036
Recruiting
Phase 2

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Advanced Microsatellite Stable Colorectal Cancer
Gilead Sciences170 enrolled5 locationsNCT07527858
Recruiting
Phase 1Phase 2

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

OsteosarcomaEwing SarcomaNeuroblastoma+4 more
Milton S. Hershey Medical Center289 enrolled10 locationsNCT06465199
Recruiting
Phase 2

Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma

Angiosarcoma Metastatic
Sun Yat-sen University69 enrolled1 locationNCT04859465